The Scientific Core: Inside Aegerion’s Medical Affairs & Clinical Support Team

Where Science Meets Compassion in Rare Disease Treatment

In the field of rare and ultra-rare diseases, scientific excellence is not just a foundation—it is a lifeline. At Aegerion Pharmaceuticals UK, our Medical Affairs & Clinical Support team serves as the scientific backbone of our organization, ensuring that everything we do is driven by evidence, informed by clinical expertise, and centered on the patient.

Our therapies may be rare, but our commitment to quality science, clinical collaboration, and medical integrity is constant and far-reaching.

Why Medical Affairs Matters in Rare Disease

Medical Affairs plays a critical role in bridging research with real-world care—a responsibility that becomes even more vital in orphan diseases, where:

• Clinical data is often limited

• Specialist expertise is scarce

• Real-world evidence plays a key role in decision-making

• Education is essential for appropriate and effective treatment

Our team is uniquely equipped to ensure that patients, healthcare professionals, and health systems are supported with the information, resources, and guidance they need to deliver meaningful outcomes.

Aegerion’s Medical Affairs & Clinical Support Capabilities

1. Scientific Engagement & Knowledge Exchange

We collaborate with leading clinicians and academic researchers across the UK and Europe to:

• Share up-to-date scientific findings and clinical guidance

• Host advisory boards, symposia, and case discussions

• Build a two-way dialogue that strengthens patient care and informs our strategy

Through trusted, non-promotional interactions, we enable informed, confident prescribing of our therapies.

2. Medical Information & HCP Support

Our dedicated medical information team provides:

• 24/7 access to product-specific scientific information

• Detailed guidance on dosage, safety, administration, and monitoring

• Training and onboarding support for new treatment centers

We respond rapidly to healthcare professional (HCP) inquiries and help clinicians make the best decisions for their patients.

3. Clinical Trial Collaboration & Evidence Generation

Working in partnership with global clinical development and R&D teams, our UK Medical Affairs team supports:

• Site selection and investigator engagement for clinical trials

• Oversight of expanded access, early access, and named patient programs

• Real-world data generation through registries and observational studies

We are committed to building the evidence base for rare disease therapies, even after launch.

4. Internal Medical Governance

We provide strategic oversight and ensure compliance with:

• ABPI Code of Practice and MHRA regulations

• Medical review of materials and programs

• Cross-functional training for commercial, access, and support teams

This ensures that science, ethics, and compliance remain at the core of our operations.

A Trusted Partner to Clinicians

Aegerion’s Medical Affairs team is built on collaboration. We see ourselves as partners to physicians, providing the scientific insights and clinical tools they need to treat rare conditions with confidence.

Whether supporting a newly diagnosed patient or guiding a complex treatment plan, our team delivers credible, evidence-based guidance every step of the way.

Our Clinical Support Commitment

Beyond science, our Clinical Support services are designed to help patients and care teams manage day-to-day treatment with:

• Patient onboarding and education resources

• Adherence monitoring and nursing support

• Therapy-specific tracking tools and follow-up coordination

This hands-on, holistic approach ensures that our therapies are used safely, effectively, and sustainably.

Science That Serves, Support That Sustains

At Aegerion Pharmaceuticals UK, Medical Affairs is not an afterthought—it is a strategic, patient-driven function that ensures our therapies do more than reach the market. They reach the right patients, at the right time, with the right guidance.

As the landscape of rare disease medicine continues to evolve, we remain grounded in one principle: credible science, clinically applied, with compassion.